Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta cell function and insulin sensitivity in type 2 diabetes patients

被引：0
|
作者：
Thomas, M. K. [1 ]
Nikooienejad, A. [1 ]
Bray, R. [1 ]
Cui, X. [1 ]
Wilson, J. [1 ]
Duffin, K. [1 ]
Milicevic, Z. [2 ]
Haupt, A. [1 ]
Robins, D. A. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Vienna, Austria
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
735
引用
收藏
页码：S354 / S354
页数：1
相关论文
共 50 条
  • [1] Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan M.
    Duffin, Kevin L.
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    [J]. DIABETES, 2019, 68
  • [2] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan
    Duffin, Kevin
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : 388 - 396
  • [3] TIRZEPATIDE, A DUAL GIP AND GLP-1 RECEPTOR AGONIST, INCREASES INSULIN SENSITIVITY AND IMPROVES PANCREATIC BETA-CELL FUNCTION IN TYPE 2 DIABETES
    Pirro, V.
    Nikooienejad, A.
    Lin, Y.
    Willency, J.
    Wilson, J.
    Duffin, K.
    Robins, D.
    Milicevic, Z.
    Haupt, A.
    Thomas, M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A165 - A165
  • [4] Weekly dual GIP/GLP-1 receptor agonist tirzepatide monotherapy improved markers of islet cell function and insulin sensitivity in people with type 2 diabetes (SURPASS-1)
    Lee, C. J.
    Thieu, V. T.
    Mao, H.
    Thomas, M. K.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 245 - 246
  • [5] The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
    Wilson, Jonathan M.
    Lin, Yanzhu
    Considine, Gary
    Cox, Amy L.
    Bowsman, Lenden M.
    Robins, Deborah A.
    Riesmeyer, Jeffrey S.
    Haupt, Axel
    Duffin, Kevin
    Ruotolo, Giacomo
    [J]. CIRCULATION, 2020, 142
  • [6] The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
    Wilson, J. M.
    Nikooienejad, A.
    Bowsman, L. M.
    Schroeder, J. M.
    Hamlin, D. M.
    Robins, D. A.
    Riesmeyer, J. S.
    Haupt, A.
    Duffin, K. L.
    Ruotolo, G.
    [J]. DIABETOLOGIA, 2019, 62 : S558 - S559
  • [7] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    [J]. JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [8] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
    Ruotolo, G.
    Roth, K. D.
    Milligan, P. L.
    Lin, Y.
    Wilson, J. M.
    Pirro, V
    Duffin, K. L.
    Haupt, A.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3056 - 3056
  • [9] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes
    Pirro, V.
    Willency, J. A.
    Wilson, J. M.
    Roth, K. D.
    Lin, Y.
    Collins, K. A. L.
    Ruotolo, G.
    Haupt, A.
    Newgard, C. B.
    Duffin, K. L.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S73 - S73
  • [10] Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity
    Rosenstock, Julio
    Coskun, Tamer
    Hartman, Mark L.
    Lou, Jitong
    Wu, Qiwei
    Du, Yu
    Gurbuz, Sirel
    Mather, Kieren J.
    Milicevic, Zvonko
    Thomas, Melissa K.
    [J]. DIABETES, 2024, 73
12345